Carla B. Washington
University of California, San Francisco
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Carla B. Washington.
Journal of Acquired Immune Deficiency Syndromes | 1998
Carla B. Washington; George E. Duran; Martha Man; Branimir I. Sikic; Terrence F. Blaschke
The anti-HIV protease inhibitors represent a new class of agents for treatment of HIV infection. Saquinavir, ritonavir, indinavir, and nelfinavir are the first drugs approved in this class and significantly reduce HIV RNA copy number with minimal adverse effects. They are all substrates of cytochrome P450 3A4, and are incompletely bioavailable. The drug transporting protein, P-glycoprotein (P-gp), which is highly expressed in the intestinal mucosa, could be responsible for the low oral bioavailability of these and other drugs which are substrates for this transporter. To determine whether these protease inhibitors are modulators of P-gp, we studied them in cell lines which do and do not express P-gp. Saquinavir, ritonavir and nelfinavir significantly inhibited the efflux of [3H]paclitaxel and [3H]vinblastine in P-gp-positive cells, resulting in an increase in intracellular accumulation of these drugs. However, similar concentrations of indinavir did not affect the accumulation of these anticancer agents. In photoaffinity labeling studies, saquinavir and ritonavir displaced [3H]azidopine, a substrate for P-gp, in a dose-dependent manner. These data suggest that saquinavir, ritonavir, and nelfinavir are inhibitors and possibly substrates of P-gp. Because saquinavir has a low bioavailability, its interaction with P-gp may be involved in limiting its absorption.
Pharmaceutical Research | 1993
Claire M. Brett; Carla B. Washington; Ronda J. Ott; Marcelo M. Gutierrez; Kathleen M. Giacomini
The therapeutic efficacy of nucleosides and nucleoside analogues as antitumor, antiviral, antiparasitic, and antiarrhythmic agents has been well documented. Pharmacokinetic studies suggest that many of these compounds are actively transported in the kidney. The goal of this study was to determine if therapeutically relevant nucleosides or analogues interact with the recently characterized Na+-driven nucleoside transport system of the brush border membrane of the human kidney. Brush border membrane vesicles (BBMV) were prepared from human kidney by divalent cation precipitation and differential centrifugation. The initial Na+-driven 3H-uridine uptake into vesicles was determined by rapid filtration. The effect of several naturally occurring nucleosides (cytidine, thymidine, adenosine), a pyrimidine base (uracil), a nucleotide (UMP), and several synthetic nucleoside analogues [zidovudine (AZT), cytarabine (Ara-C), and dideoxycytidine (ddC)] on Na+–uridine transport was determined. At a concentration of 100 µM the naturally occurring nucleosides, uracil, and UMP significantly inhibited Na+-uridine transport, whereas the three synthetic nucleoside analogues did not. Adenosine competitively inhibited Na+-uridine uptake with a Ki of 26.4 µM (determined by constructing a Dixon plot). These data suggest that naturally occurring nucleosides are substrates of the Na+–nucleoside transport system in the renal brush border membrane, whereas synthetic nucleoside analogues with modifications on the ribose ring are not. The Ki of adenosine is higher than clinically observed concentrations and suggests that the system may play a physiologic role in the disposition of this nucleoside.
Clinical Pharmacology & Therapeutics | 2003
Carla B. Washington; Charles Flexner; Lewis B. Sheiner; Susan L. Rosenkranz; Yoninah Segal; Judith A. Aberg; Terrence F. Blaschke
The aim of this study was to determine whether pharmacokinetic interactions between the protease inhibitors saquinavir soft gel, nelfinavir, and ritonavir are affected by the timing of administration.
American Journal of Physiology-renal Physiology | 1997
Juan Wang; Sheng-Fang Su; Mark J. Dresser; Marci E. Schaner; Carla B. Washington; Kathleen M. Giacomini
Drug Metabolism and Disposition | 2000
Carla B. Washington; Hugh Wiltshire; Martha Man; Tina Moy; Steve R. Harris; Eric Worth; Paul Weigl; Zhenmin Liang; David Hall; Lorraine Marriott; Terrence F. Blaschke
Drug Metabolism and Disposition | 2000
Lei Zhang; Wenche Gorset; Carla B. Washington; Terrence F. Blaschke; Deanna L. Kroetz; Kathleen M. Giacomini
Drug Metabolism and Disposition | 1993
J. R. Cashman; S. B. Park; Zi-Chen Yang; Carla B. Washington; D. Y. Gomez; Kathleen M. Giacomini; Claire M. Brett
Journal of Biological Chemistry | 1995
Carla B. Washington; Kathleen M. Giacomini
Pharmaceutical Research | 1998
Carla B. Washington; Kathleen M. Giacomini; Claire M. Brett
Pharmaceutical Research | 1996
Carla B. Washington; Kathleen M. Giacomini